Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...

Mounjaro and Zepbound have shown impressive prescription growth trends ... week increase to 212,962 scripts in the same period. These products have positioned Eli Lilly as a leader in the rapidly ...

Mounjaro and Zepbound have shown impressive prescription growth trends, with Mounjaro experiencing ... saw a 20.7% week-over-week increase to 212,962 scripts in the same period. These products have ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

The firm also highlighted the overall growth trend for another Eli Lilly product, Mounjaro, within the broader diabetes GLP-1 market. Meanwhile, Leerink Partners maintained an Outperform rating on ...

Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity treatment counterpart Zepbound brought in $1.9 ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks. In a fresh appearance on CNBC's Squawk on the Street, Jim Cramer cautioned ...